Clinical trial Recruiting at 1 site Observational Ages 18 and up

Assessing quality of life in patients with cutaneous lymphoma

Official title: Assessment of Quality of Life in Cutaneous Lymphoma Patients Using the Skindex29

Run by City of Hope Medical Center · NCT04670874 · Data updated 2026-11-12

This study looks at how living with cutaneous lymphoma affects adults' quality of life and what support they might need to feel better.

More Cutaneous T Cell Lymphoma trials

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment1250 (estimated)
SponsorCity of Hope Medical Center
Academic / other
Locations1 site (Duarte, California)
StatusRecruiting
StartedAugust 17, 2023
Main results expectedJanuary 24, 2034
Study endsJanuary 24, 2034
Registry record updatedJanuary 28, 2026
Trial IDNCT04670874 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are adults with a presumed or confirmed diagnosis of cutaneous lymphoma.

Probably not a fit

Patients without a diagnosis of cutaneous lymphoma or those who do not agree to participate in the research may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study evaluates the quality of life in adult patients diagnosed with cutaneous lymphoma using the Skindex-29 questionnaire. It aims to identify the psychosocial needs of patients, assess the burden of pruritus, and correlate quality of life with demographic and clinical factors. Additionally, the study tracks patients' understanding of their diagnosis and their need for resources related to their care. By gathering this information, the study seeks to improve the overall quality of life for individuals affected by this rare type of cancer.

Why it matters

Potential benefit: If successful, this study could lead to improved support and resources for patients with cutaneous lymphoma, enhancing their quality of life.

How similar studies have gone: While there have been studies assessing quality of life in cancer patients, this specific focus on cutaneous lymphoma and the use of the Skindex-29 questionnaire is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Agreement to participate in the research study
* Presumed or confirmed diagnosis of CL

Where it's running

  • City of Hope Medical Center
    Duarte, California, United States
    Recruiting

Study contacts

  • Principal investigator: Christiane Querfeld — City of Hope Medical Center

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

  • Ruxolitinib maintenance after stem cell transplant for T‑cell lymphoma

    This phase II trial tests whether taking ruxolitinib after a stem cell transplant can lower the chance of relapse and graft‑versus‑host disease for people treated for T‑cell lymphoma.

    Recruiting at 2 sites Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio and 1 other locations · NCT07356245

  • Ropeginterferon treatment for cutaneous T‑cell lymphoma

    This trial tests whether ropeginterferon-alfa-2b helps people with cutaneous T‑cell lymphoma who have not responded adequately to multiple prior skin-directed therapies.

    Recruiting Phase 1 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT07047885

  • Personalized exercise and nutrition program to reduce cancer-related fatigue

    This program will try a personalized exercise and diet plan to reduce fatigue for adults with indolent lymphomas (including CLL/SLL and follicular lymphoma).

    Recruiting UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT06860880

  • Golidocitnib treatment for relapsed indolent T/NK-cell lymphomas

    This study is testing if a new oral medication called Golidocitnib can help people with relapsed indolent T/NK-cell lymphomas feel better after other treatments haven't worked.

    Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality and 1 other locations · NCT06716658

  • Tofacitinib cream for treating early-stage Cutaneous T-cell Lymphoma

    This study is testing if a new cream can help people with early-stage Cutaneous T-cell Lymphoma feel better and improve their skin after 12 weeks of treatment.

    Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT06698822

  • Systemic treatments for cutaneous T‑cell lymphoma

    This project looks at how different systemic treatments are used in adults with cutaneous T‑cell lymphoma to see which approaches are linked to longer disease control in routine care.

    Recruiting at 9 sites Fondazione Italiana Linfomi - ETS · Ancona and 17 other locations · NCT06588868

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.